D'adamio Lab

Rutgers Biomedical and Health Sciences

PHARMACOLOGY

Newark · United States

NIH-funded
Rate this labNo reviews yet — be the first.

Research focus

NIH R01 · 2025

Trem2-mediated microglia-neuronal axis in Alzheimer disease pathogenesis

Abstract Alzheimer’s Disease (AD) is the most common cause of ageing-dependent dementia in the world and is associated with cerebral amyloid plaques, mostly composed of Aβ peptides, and intraneuronal neurofibrillary tangles, mostly composed by hyperphosphorylated tau. The impacts of AD on patients, families, caregivers and society are shattering. Regrettably, AD-modifying drugs are unavailable underscoring the scant understanding of AD pathogenesis. ~5% of AD cases have early onset (<65 yo) and are due to Familial autosomal dominant mutations in APP, PSEN1 and PSEN2 (FAD); ~95% of cases are sporadic with late onset (>65 yo, SAD). Yet, commonly used animal organisms model FAD. This may be an…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.

Reviews

← All labs at Rutgers Biomedical and Health Sciences